Bayer
100 Bayer Road
Whippany
New Jersey
07981
United States
Tel: 1-877-229-3727
Website: http://www.career.bayer.us/
Email: careersus@bayer.com
About Bayer
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
484 articles with Bayer
-
Build a Foundation for Plentiful Potatoes
1/10/2019
Tempting tubers get their good looks and heavy weights from healthy roots.
-
Bayer Statement on Updated Protocol for Postmarket Essure Study
12/20/2018
Safety and efficacy of Essure® have not changed
-
HitGen and Bayer Enter DNA-Encoded Library Based Research Collaboration
12/20/2018
Program could lead to new crop protection solutions for farmers worldwide
-
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
-
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
12/17/2018
Bayer announced today that the Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy in the prescribing information for Betaseron® (Interferon beta 1b, IFNß-1b), which is indicated for the treatment of relapsing remitting multiple sclerosis (RRMS).
-
Brigham Young University Makes History, Sets New World Record in Bayer Alka-Rocket Challenge
12/12/2018
Brigham Young University student rocketeers blasted their way into history today, setting a new GUINNESS WORLD RECORDS title for Highest launch of an Alka-Rocket* in the 2018 Bayer Alka-Rocket Challenge.
-
It seems like every time we turned around this year, there was an exciting or—on a more visceral level, “Hey, that’s cool!” science story. Here’s a look at the top 9 really cool life science discoveries of the year, from outer space, to peanut allergies, to tortoise genomes.
-
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
-
In July 2017, Bayer launched a three-year, Phase III ASTEROID clinical trial of vilaprisan in patients with symptomatic uterine fibroids, with the intention of recruiting more than 3,600 patients in 900 sites in 40 countries.
-
Bayer Presents Five-Year Outcomes Data from the PROTECT VIII Extension Study at the 60th American Society of Hematology Annual Meeting
12/4/2018
Study finds long-term safety and efficacy in subset of 33 hemophilia A patients who received treatment with Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) for five years was consistent with previous data analysis
-
NRGene Announces Expanded Licensing Agreement with Bayer for the GenoMAGIC™ Platform
12/3/2018
Following successful evaluation, Bayer has chosen the GenoMAGIC™ platform to support its advanced molecular breeding program in several key crops
-
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the repo...
-
Bayer Pledges 5 Million Hands-On Science Learning Experiments for Children in the United States by 2025
11/30/2018
New Pledge Accelerates 20+ Year Commitment to Improving Science Education; Program Kicks Off with Unveiling of "Science Studio" Alexa Skill
-
Class Action Certification YASMIN® & YAZ® Sold in Canada (Excluding Ontario and Québec)
11/29/2018
A class action, Dembrowski v. Bayer Inc., QBG 1611 of 2009, commenced in the Court of Queen’s Bench for Saskatchewan, was certified to advance claims regarding the combination oral contraceptives Yasmin® and Yaz® that Bayer marketed in Canada.
-
Bayer will cut 12,000 jobs as it prepares an overhaul of its business that includes exiting its animal health business as it deals with the fallout from its $63 billion acquisition of Monsanto. Additionally, the company said it will sell its 60 percent stake in Germany-based site services provide...
-
Bayer to Present Hematology Data at the 2018 American Society of Hematology Annual Meeting
11/28/2018
Bayer announced today that seven abstracts from its Hemophilia portfolio and development pipeline have been accepted for presentation during Scientific Sessions at the 2018 American Society of Hematology (ASH) Annual Meeting, December 1 – December 4, in San Diego, CA.
-
US Bioservices Selected by Bayer and Its Collaboration Partner Loxo Oncology, Inc. to Dispense Vitrakvi® (larotrectinib)
11/28/2018
New therapy approved to treat gene fusions across several different types of tumors
-
Bayer U.S. Adds Mitchell, Parrish to Senior Leadership Roles
11/27/2018
Bayer U.S. today announced the appointments of Albert J. Mitchell and Michael Parrish to two of the company's corporate affairs leadership positions.
-
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
11/27/2018
First treatment with a tumor-agnostic indication at the time of initial FDA approval
-
Bayer to give $120,000 through new Grants Fur Families program benefitting domestic violence survivors and their pets
11/27/2018
Grant program raises awareness of the role pets play for survivors - helping to increase the number of domestic violence shelters offering on-site pet facilities